logo
Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > Chemical Intermediates > (R)-5-bromo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine CAS 877399-00-3

(R)-5-bromo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine CAS 877399-00-3

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 877399-00-3

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Bag,Drum

Delivery Time: 7-15 days

Payment Terms: L/C, D/A, T/T, Western Union

Supply Ability: TON

Get Best Price
Highlight:

(R)-5-bromo-3-(1-(2

,

6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine

,

CAS 877399-00-3

CAS NO::
877399-00-3
Appearance::
Pale Yellow Solid
Molecular Formula::
C13H10BrCl2FN2O
Molecular Weight::
380.04000
EINECS NO::
700-798-7
MDL NO::
MFCD18207061
CAS NO::
877399-00-3
Appearance::
Pale Yellow Solid
Molecular Formula::
C13H10BrCl2FN2O
Molecular Weight::
380.04000
EINECS NO::
700-798-7
MDL NO::
MFCD18207061
(R)-5-bromo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine CAS 877399-00-3

Product Description:

Product Name: (R)-5-bromo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine CAS NO: 877399-00-3

 

 

Synonyms:

[5-Bromo-3-[(1R)-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-yl]amine;

(R)-5-Bromo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine;

QC-4374;

 

 

Chemical & Physical Properties:

Appearance: Pale yellow solid

Assay :≥99.0%

Density: 1.643

Melting Point: 107.0 to 111.0℃

Boiling Point: 423.4±40.0℃(Predicted)

storage Temp.: Keep in dark place,Inert atmosphere,2-8℃

Flash Point: 209.9±27.3℃

Vapour Pressure: 0.0±1.0 mmHg at 25℃

Index of Refraction: 1.626

 

 

Safety Information:

HS Code: 2933399090

 

 

[5-Bromo-3- [(1R) - (2,6-dichloro-3-fluorophenyl) ethoxy] pyridin-2-yl] amine is an intermediate of crizotinib, and crizotinib is a multi-target protein kinase inhibitor developed by Pfizer to inhibit ATP competition in Met/ALK/ROS. It has been confirmed that crizotinib has significant clinical efficacy in the human body in tumor patients with abnormal ALK, ROS, and MET kinase activity.

 

 

If you are interested in our products or have any questions, please feel free to contact us!

 

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.